This is a routine, pre-planned sale under a 10b5-1 plan and not an immediate red flag. However, traders should monitor for actual execution around April 10 and watch for additional filings that may indicate broader insider selling trends.
CGEN drugs
CGEN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 13 $2.76entry
- T+1 · 7mo ago +4.35%α +3.14% · $2.88
- T+5 · 7mo ago +4.35%α +1.05% · $2.88
- T+20 · 6mo ago +3.99%α −3.74% · $2.87
- T+60 · 4mo ago −12.68%α −21.60% · $2.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zurit Levine, an officer of Compugen Ltd, filed a Form 144 to notify intent to sell up to 2,000 ordinary shares, valued at approximately $49,600 based on the current market price. The shares are part of a 10b5-1 sale plan adopted on December 24, 2025, with the proposed sale date on April 10, 2026.
Key Facts
- Reporting person: Zurit Levine, Officer of Compugen Ltd
- Number of shares proposed for sale: 2,000
- Approximate value of shares: $49,600 (based on $24.80/share implied price)
- Sale planned under a 10b5-1 plan adopted on December 24, 2025
- Proposed sale date: April 10, 2026
- Shares originated from the Employee Stock Option Plan, granted August 3, 2023
Financial Impact
Minimal dilution or financial impact; proposed sale of $49,600 worth of shares represents less than 0.02% of Compugen's $244M market cap
Risk Factors
- Perception of lack of confidence if multiple insiders initiate similar sales
- Execution risk if the sale proceeds near-term and adds downward pressure on a low-volume stock
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001976408-26-000324 |
| Document: 0001976408-26-000324-index.html | 0001976408-26-000324 |
| Document: 0001976408-26-000324.txt | 0001976408-26-000324 |
Track record
9 reports on CGEN
Filters
- Nov 9, 20267d ago 6-K Neutral 4/10 Entry $2.14 Now $2.04 −4.67% settles Dec 8
- Aug 3, 202615w ago 6-K Neutral 2/10 Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Aug 3, 202615w ago 6-K Neutral 4/10 Entry $2.38 to $2.56 Now $2.04 −14.29% ▲ +7.56% +6.33% vs SPY
- Jun 9, 202623w ago EFFECT Neutral 3/10 Entry $2.02 to $2.39 Now $2.04 +0.99% ▲ +18.32% +16.87% vs SPY
- May 18, 202626w ago 6-K Neutral 4/10 Entry $2.86 to $2.03 Now $2.04 −28.67% ▼ −29.02% −30.60% vs SPY
- Apr 24, 202629w ago Insider Cluster Neutral 2/10 Entry $3.10 to $2.61 Now $2.04 −34.19% ▼ −15.81% −19.83% vs SPY
- Apr 14, 202631w ago Insider Cluster Neutral 2/10 Entry $2.88 to $2.87 Now $2.04 −29.17% ▼ −0.35% −6.64% vs SPY
- Apr 13, 202631w ago 144 Neutral 3/10 Viewing Entry $2.76 to $2.87 Now $2.04 −26.09% ▲ +3.99% −3.74% vs SPY
- Mar 26, 202633w ago Insider Cluster Neutral 3/10 Entry $2.06 to $3.10 Now $2.04 −0.97% ▲ +50.49% +39.82% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers